Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
ID07282834

Randomized Phase II Trial of Heated Versus Pressurized/Aerosolized Chemotherapy (HIPEC vs. PIPAC) for Peritoneal Carcinomatosis

Led by Patrick Wagner, MD, FACS · Updated on 2026-02-27

200

Participants Needed

1

Research Sites

256 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating treatment options for Peritoneal Carcinomatosis (PC), a condition where cancer spreads inside the abdomen, causing pain and nutritional issues. The study compares two methods of delivering chemotherapy directly into the abdomen: Heated Intra-Peritoneal Chemotherapy (HIPEC) and Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Both methods use the chemotherapy drug mitomycin C but have not been directly compared for safety, tolerability, effectiveness, and overall value. Participants will be randomly assigned to receive either HIPEC or PIPAC. HIPEC involves circulating heated chemotherapy through the abdomen for 90 minutes during surgery, repeated up to three times about six weeks apart. PIPAC delivers chemotherapy as a pressurized aerosol laparoscopically for 30 minutes, also repeated up to three times at similar intervals. Before treatment, diagnostic laparoscopies and biopsies will be performed to assess eligibility and collect tumor tissue for analysis. During the study, patients will undergo quality-of-life surveys at the start and after each chemotherapy treatment. Follow-up laparoscopies will check treatment effects and side effects. Although participants are followed for up to five years, no extra study visits are required after treatment. Researchers will monitor adverse events, surgical complications, treatment tolerability, and effectiveness over time to learn which method may offer better results for patients with PC.

CONDITIONS

Brief Title

Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female aged 18 to 80 years
  • Biopsy-proven or clinically suspected peritoneal carcinomatosis
  • Received at least three months of standard systemic chemotherapy with persistent disease at randomization
  • Not a candidate for surgical cytoreduction at time of laparoscopy
  • Women of childbearing potential must have a negative pregnancy test and use contraception during the study
  • Able to read, understand English, and provide informed consent
Not Eligible

You will not qualify if you...

  • Eligible for definitive cytoreductive surgery at enrollment
  • Significant blood, liver, or kidney problems as shown by specific lab test limits
  • Use of any investigational drug within 30 days before enrollment
  • Systemic therapy within 14 days before randomization
  • Allergy or contraindication to chemotherapy used in this study
  • Medical contraindication to laparoscopic or complex cytoreductive surgery
  • Pregnant or breastfeeding females
  • Expected non-compliance with study schedule or procedures as judged by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 screening and enrollment visit (in-person)

Treatment

Duration - Approximately 12 to 18 weeks

Participants receive three rounds of chemotherapy administered laparoscopically using either heated intra-peritoneal chemotherapy (HIPEC) or pressurized/aerosolized intra-peritoneal chemotherapy (PIPAC), each about six weeks apart. Biopsies of tumor tissue will be collected at each treatment for analysis.

3 laparoscopic treatment visits

Post-treatment Assessment

Duration - Within a few weeks after the last treatment

Participants undergo a final laparoscopy to assess the effects of treatment and check for side effects.

1 follow-up laparoscopy visit

Trial Site Locations

Total: 1 location

1

Allegheny Health Network West Penn Hospital

Pittsburgh, Pennsylvania, United States, 15224

Actively Recruiting

Loading map...

Research Team

P

Patrick Wagner, MD

A

AHN Clinical Trial Contact Clinical Trial Contact

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Feasibility Study of MRI Guided Stereotactic Ablative Radi...

Abdominal Cancer

Actively Recruiting

1 location

A Phase I Trial of Intraperitoneal Mesothelin-Targeted CAR T...

Mesothelin Positive

Actively Recruiting

7 locations

A Phase 2 Open Label Study of Intraperitoneal Alpha-emitting...

Peritoneal Carcinomatosis

Actively Recruiting

10 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here